BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 31419091)

  • 1. Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape.
    Glassberg MK
    Am J Manag Care; 2019 Jul; 25(11 Suppl):S195-S203. PubMed ID: 31419091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving outcomes and managing costs in idiopathic pulmonary fibrosis.
    Morrow T
    Am J Manag Care; 2019 Jul; 25(11 Suppl):S204-S209. PubMed ID: 31419090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Idiopathic Pulmonary Fibrosis.
    Pleasants R; Tighe RM
    Ann Pharmacother; 2019 Dec; 53(12):1238-1248. PubMed ID: 31280590
    [No Abstract]   [Full Text] [Related]  

  • 4. Current approaches to the management of idiopathic pulmonary fibrosis.
    Raghu G; Richeldi L
    Respir Med; 2017 Aug; 129():24-30. PubMed ID: 28732832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
    Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
    Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developments in the management of idiopathic pulmonary fibrosis.
    Drug Ther Bull; 2015 Jul; 53(7):78-81. PubMed ID: 26159700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiopathic pulmonary fibrosis: A guide for nurse practitioners.
    Vega-Olivo M; Criner GJ
    Nurse Pract; 2018 May; 43(5):48-54. PubMed ID: 29465476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idiopathic pulmonary fibrosis: the turning point is now!
    Funke M; Geiser T
    Swiss Med Wkly; 2015; 145():w14139. PubMed ID: 26024356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis.
    Aiello M; Bertorelli G; Bocchino M; Chetta A; Fiore-Donati A; Fois A; Marinari S; Oggionni T; Polla B; Rosi E; Stanziola A; Varone F; Sanduzzi A
    Pulm Pharmacol Ther; 2017 Jun; 44():7-15. PubMed ID: 28257817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological management of IPF.
    Borie R; Justet A; Beltramo G; Manali ED; Pradère P; Spagnolo P; Crestani B
    Respirology; 2016 May; 21(4):615-25. PubMed ID: 27072575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health economic evaluation in idiopathic pulmonary fibrosis in France.
    Porte F; Cottin V; Catella L; Luciani L; Le Lay K; Bénard S
    Curr Med Res Opin; 2018 Oct; 34(10):1731-1740. PubMed ID: 29368948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
    Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
    Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
    Wongkarnjana A; Yanagihara T; Kolb MR
    Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.
    Jo HE; Troy LK; Keir G; Chambers DC; Holland A; Goh N; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford H; Chapman S; Reynolds PN; Glaspole I; Beatson D; Jones L; Hopkins P; Corte TJ
    Respirology; 2017 Oct; 22(7):1436-1458. PubMed ID: 28845557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
    Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
    Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations.
    Jo HE; Randhawa S; Corte TJ; Moodley Y
    Drugs Aging; 2016 May; 33(5):321-34. PubMed ID: 27083934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiopathic Pulmonary Fibrosis: A Case Discussion.
    Felton MK; Bautista B; Morrow LE; Malesker M
    Consult Pharm; 2017 Jul; 32(7):406-411. PubMed ID: 28701252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential.
    Raghu G
    Eur Respir Rev; 2017 Sep; 26(145):. PubMed ID: 28954769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idiopathic pulmonary fibrosis.
    Koudstaal T; Wijsenbeek MS
    Presse Med; 2023 Sep; 52(3):104166. PubMed ID: 37156412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management.
    van Cleemput J; Sonaglioni A; Wuyts WA; Bengus M; Stauffer JL; Harari S
    Adv Ther; 2019 Feb; 36(2):298-317. PubMed ID: 30554332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.